As of June 12, 2025, Addex Therapeutics Ltd (ADXN.SW) reports a EV/EBITDA of -3.72.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Addex Therapeutics Ltd's EV/EBITDA to Peers
To better understand Addex Therapeutics Ltd's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Addex Therapeutics Ltd (ADXN.SW) | -3.72 |
| Circassia Group PLC (CIR.L) | 29.62 |
| Synthaverse SA (BML.WA) | 20.56 |
| Basilea Pharmaceutica AG Allschwil (BSLN.SW) | 10.26 |
| Erytech Pharma SA (ERYP.PA) | 0.11 |
| Polyphor AG (POLN.SW) | -0.11 |
Compared to its competitors, Addex Therapeutics Ltd's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.